関連ニュース

Mirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIR

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guid